While Eli Lilly and Novo Nordisk dominate the obesity-drug market, there’s a vast field of would-be competitors closing in behind them — and the most successful among those next-wave contenders stand to capture up to 20% of the lucrative market, analysts say.
Obesity drugs’ next wave: These companies could snag 20% of GLP-1 market, analysts say
